PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!
Visit https://www.peervoice.com/FKG860 to view the entire programme with slides. After completing “GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!”, participants will be able to: Differentiate between GnRH antagonists and LHRH agonists; Describe the recent clinical trial data assessing GnRH antagonist therapy for the treatment of prostate cancer; Discuss if GnRH antagonist therapy may lead to different clinical outcomes."